Share this
interview: fasha mahjoor, founder of neoteryx and phenomenex
by Neoteryx Microsampling on Nov 19, 2018 4:45:00 AM
Guided by his entrepreneurial instincts and desire to better the human condition, Fasha Mahjoor founded Phenomenex in 1982 jumping into the complex field of separation sciences and chromatography. After 34 years at the helm of the extremely successful venture, he sold Phenomenex in December 2016 to the Danaher Corporation, leaving himself time to focus on Neoteryx, a company he established in 2014 dedicated to developing novel microsampling technologies that modernize how and where blood samples are collected.
We asked the businessman and philanthropist what drove him to take on yet another challenging but massive opportunity. His answers shed light on what Neoteryx stands for and where it may go from here.
In 2014, Phenomenex was a well-established, booming business yet you decided to embark on a new venture with Neoteryx. What motivated you to take this bold leap of faith?
It was an easy decision, actually! While sitting in a crowded room waiting for my blood to be drawn for lab tests I couldn’t help but be irritated by the inconvenience of it all, especially knowing what was brewing in an R&D incubator within Phenomenex – blood microsampling technology. I decided that day to spin the incubator into its own entity to accelerate the release of a technology that would modernize blood collection and thus laboratory testing making it more convenient, comfortable, and accessible.
You say Neoteryx’s blood microsampling technology modernizes blood collection. How so?
Our Mitra® Microsampling Device based on VAMS® technology, creates a smarter blood sampling event. Precise, volumetrically accurate specimens of blood or other biological fluids can be collected anywhere, at any time, by almost anyone, from a simple finger-stick. This allows for remote sampling, taking collection out of traditional clinics.
Remote sampling opens new applications, pathways and possibilities across drug clinical trials, telemedicine, therapeutic drug monitoring, personalized medicine, addiction recovery, elder care, and the entire spectrum of health and wellness.
Neoteryx has been at it for just over four years now, what makes blood microsampling continue to be worth the risk?
My passion is architecture. Therefore, from an aesthetic perspective, the absurd simplicity of our microsampling devices and knowing what can be accomplished with such a simple little thing is what lights a fire in me every day. Yet, it’s remarkable how much muscle, mind, and science it takes to work on something so simple!
The applications, of course, are what matter here. I’ve seen our technology improving lives for malnourished children in Africa who don’t have access to testing laboratories. It’s helping organ transplant patients live fuller lives than they imagined possible, whether they are mountaineering or eliminating lengthy drives to and from transplant clinics.
Our technology is enabling consumers to take a more personalized approach in managing their own health. When I see an opportunity to achieve new business success and more importantly improve lives and convenience on all fronts on top of that, I can hardly afford the risk of not doing it!
Didn’t the company Theranos have grand visions to change the way blood was collected and tested?
I really can’t comment on what the Theranos vision was. All I can tell you is that our products are simple; they speak for themselves! They do exactly and precisely what they are supposed to do, as proven by dozens of third party scientific publications and hundreds of users.
Who are the users of your microsampling technology?
We have hundreds of people using our microsampling technology, all over the world, in the medical, pharmaceutical, research, forensic toxicology, and healthcare fields. And new users are jumping on board every single day. What all these end-users have in common is that they are creating possibilities that didn’t exist before! Clinical trials are going virtual. Potential new blood biomarkers are being researched. Pediatric patients are avoiding painful blood draws. Elderly patients can age gracefully in place.
Can you give some specific end-user examples?
Off the top of my head:, Quest Diagnostics, Ghent University Hospital, Swiss Tropical Institute, Alcala Labs, Exagen Diagnostics, UCB Biopharma, Charles River Laboratories, Altasciences, York Bioanalytical, and Labor Krone. The list goes on and on.
How do you envision the future of Neoteryx and blood microsampling?
We have created a strong culture that will see this technology through the many opportunities on the horizon. My legacy will be to cultivate the leadership and the partnerships, as I did at Phenomenex, that will allow it to flourish more and more as time goes on. Of course, the road to success requires lots of cooperation, collaboration, and support to execute on the ambitious plans we’ve laid out.
I have many visions of what Neoteryx’s future glory may look like. And yet, my ultimate hope is that this will change the world in ways even I never imagined.
# # #
Editorial Note: The original 2018 interview transcript has not been modified, but please note that Neoteryx was acquired by Trajan Scientific and Medical in 2021. Moving forward, Neoteryx is the microsampling product brand of Trajan.
Share this
- Microsampling (206)
- Research, Remote Research (119)
- Venipuncture Alternative (106)
- Clinical Trials, Clinical Research (83)
- Mitra® Device (74)
- Therapeutic Drug Monitoring, TDM (51)
- Dried Blood Spot, DBS (38)
- Biomonitoring, Health, Wellness (31)
- Infectious Disease, Vaccines, COVID-19 (24)
- Blood Microsampling, Serology (22)
- Decentralized Clinical Trial (DCT) (22)
- Omics, Multi-Omics (20)
- Specimen Collection (17)
- Toxicology, Doping, Drug/Alcohol Monitoring, PEth (17)
- hemaPEN® Device (13)
- Preclinical Research, Animal Studies (12)
- Skin Microsampling, Microbiopsy (12)
- Pharmaceuticals, Drug Development (9)
- Harpera Device (5)
- Industry News, Microsampling News (5)
- Antibodies, MAbs (3)
- Company Press Release, Product Press Release (3)
- Environmental Toxins, Exposures (1)
- December 2024 (2)
- November 2024 (1)
- October 2024 (3)
- September 2024 (1)
- June 2024 (1)
- May 2024 (1)
- April 2024 (4)
- March 2024 (1)
- February 2024 (2)
- January 2024 (4)
- December 2023 (3)
- November 2023 (3)
- October 2023 (3)
- September 2023 (3)
- July 2023 (3)
- June 2023 (2)
- April 2023 (2)
- March 2023 (2)
- February 2023 (2)
- January 2023 (3)
- December 2022 (2)
- November 2022 (3)
- October 2022 (4)
- September 2022 (3)
- August 2022 (5)
- July 2022 (2)
- June 2022 (2)
- May 2022 (4)
- April 2022 (3)
- March 2022 (3)
- February 2022 (4)
- January 2022 (5)
- December 2021 (3)
- November 2021 (5)
- October 2021 (3)
- September 2021 (3)
- August 2021 (4)
- July 2021 (4)
- June 2021 (4)
- May 2021 (4)
- April 2021 (3)
- March 2021 (5)
- February 2021 (4)
- January 2021 (4)
- December 2020 (3)
- November 2020 (5)
- October 2020 (4)
- September 2020 (3)
- August 2020 (3)
- July 2020 (6)
- June 2020 (4)
- May 2020 (4)
- April 2020 (3)
- March 2020 (6)
- February 2020 (3)
- January 2020 (4)
- December 2019 (5)
- November 2019 (4)
- October 2019 (2)
- September 2019 (4)
- August 2019 (4)
- July 2019 (3)
- June 2019 (7)
- May 2019 (6)
- April 2019 (5)
- March 2019 (6)
- February 2019 (5)
- January 2019 (8)
- December 2018 (3)
- November 2018 (4)
- October 2018 (7)
- September 2018 (6)
- August 2018 (5)
- July 2018 (8)
- June 2018 (6)
- May 2018 (5)
- April 2018 (6)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (2)
- November 2017 (3)
- October 2017 (2)
- September 2017 (4)
- August 2017 (2)
- July 2017 (4)
- June 2017 (5)
- May 2017 (6)
- April 2017 (6)
- March 2017 (5)
- February 2017 (4)
- January 2017 (1)
- July 2016 (3)
- May 2016 (1)
- April 2016 (2)
Comments (3)